Jiangsu Hengrui Pharmaceuticals (01276) released its financial results for the first quarter, with a net profit attributable to shareholders of 2.282 billion RMB, an increase of 21.78% year-on-year.

Jiangsu Hengrui Pharmaceuticals (01276) announces that in the first quarter of 2026, the group achieved a total operating income of 8.141 billion yuan (unit in following), representing an increase of 12.98% compared to the same period last year. The net profit attributable to shareholders of the listed company was 2.282 billion yuan, showing a year-on-year increase of 21.78%, with basic earnings per share of 0.34 yuan. In the first quarter of 2026, the company's sales revenue from innovative drugs reached 4.526 billion yuan, an increase of 25.75% compared to the previous year, accounting for 61.69% of total drug sales revenue. Within the innovative drug sales revenue, revenue from anti-tumor products reached 3.313 billion yuan, up 11.63% year-on-year, representing 73.20% of total innovative drug sales revenue. Revenue from non-cancer products was 1.213 billion yuan, showing a significant increase of 92.13%, accounting for 26.80% of total innovative drug sales revenue. With the continuous approval of new products and indications, as well as the gradual inclusion of innovative drugs covered by medical insurance, the company aims to achieve over 30% growth in innovative drug sales revenue for the full year. Revenue from licensing business of innovative drugs to external parties during the reporting period was 0.787 billion yuan, mainly recognized based on the completion progress of performance obligations by GSK. Due to factors such as national and local centralized procurement and the company's strategic resource contraction, sales revenue from generic drugs decreased during the reporting period. As sales revenue from innovative drugs continues to grow, the proportion of generic drug sales revenue in total sales revenue will gradually decrease, further optimizing the company's revenue structure and strengthening the stable development pattern driven by innovation.